Approval · Notice of Compliance 29674 · 2022
BEOVU: Notice of Compliance 29674
Issued November 30, 2022
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 29674
- Date
- November 30, 2022
- Company
- Novartis Pharmaceuticals Canada Inc.Montreal, Quebec, Canada
- Product type
- Biologic
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Other
- Reason
- New indication: -Beovu (brolucizumab injection) is indicated for the treatment of diabetic macular edema (DME)
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| BEOVU | Not yet assigned | — |
Medicinal ingredients
- BROLUCIZUMAB 6 MG per 0.05ML